Phase 2 Study of Dose‐Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early‐Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer